Pfizer Announced Its Oral COVID-19 Medication May Be Available This Year

Empty vials of “Comirnaty” the COVID-19 vaccine from Pfizer BioNTech (REUTERS / Hannibal Hanschke)

The Oral drug to treat COVID-19 made by the US laboratory Pfizer could be available this year if it gets clearance, company sources said Tuesday.

Such an oral medication could be used to treat already infected patients or as a preventive measure to prevent the virus from spreading in a home after a family member contracts the virus.

Pfizer executives said that the potential treatment shows signs of being effective against several variants of the virus, and they were optimistic awaiting the research data expected later this year.

“It is a really important medicine for the world… fingers crossed as we await the results, “said Pfizer Chief Scientific Officer Mikael Dolsten.

The Scientific Director of Pfizer, Mikael Dolsten (REUTERS / Neil Hall / File Photo)
The Scientific Director of Pfizer, Mikael Dolsten (REUTERS / Neil Hall / File Photo)

In the event that the studies and analysis by health entities are positive, the company could increase production of the drug by next year.

Currently, the American laboratory Merck is waiting for the US and European entities to give the emergency authorization to its pill against covid-19, an easy remedy to administer.

The tratment of molnupiravir, administered to patients within days of testing positive, halves the risk of hospitalization and death, according to a clinical trial conducted by Merck, also known as MSD outside of the United States.

El CEO de Pfizer, Albert Bourla (John Thys /Pool via REUTERS/File Photo)
El CEO de Pfizer, Albert Bourla (John Thys /Pool via REUTERS/File Photo)

Pfizer raises its earnings forecasts

Pfizer, meanwhile, on Tuesday raised its estimates of annual revenue from its Comirnaty covid vaccine, developed together with the German biotechnology company BioNTech, thanks to the strong demand outside the United States.

Now the company hopes to sell the vaccine this year for $ 36 billion, when the previous forecast was 33,500 million.

“More than 75% of the increase in Comirnaty’s revenue in the third quarter of 2021 comes from countries outside the United States”said Pfizer CEO Albert Bourla in the company’s quarterly results statement.

View of the application of a vaccine against covid-19 in Arleta, California, in a file photograph (EFE / Caroline Brehman)
View of the application of a vaccine against covid-19 in Arleta, California, in a file photograph (EFE / Caroline Brehman)

“We are on track to meet our goal of supply at least 2 billion doses to low- and middle-income countries by the end of 2022 ″He added, noting that half of these doses would be sold to the US government at cost for distribution in the world’s poorest countries.

In the whole of the year, Pfizer plans to supply 2.3 billion vaccines worldwide.

At the end of October, the US Food and Drug Administration (FDA) approved Comirnaty for children ages 5 to 11, paving the way for a major new vaccination campaign in the country.

A group of experts from the Centers for Disease Control and Prevention (CDC) is meeting Tuesday to decide whether the vaccine is recommended for younger children.

From July to September, Pfizer posted sales of $ 24.1 billion, more than the $ 22.7 billion expected by Wall Street.

(With information from Reuters, AP, AFP)

Keep reading:

Israel reopens, but remains cautious despite falling infections and deaths
The Centers for Disease Control defines whether to recommend the Pfizer vaccine for children ages 5 to 11 in the US
Russia hits another daily record for COVID deaths amid Vladimir Putin’s paid holidays
Controlling your insulin level reduces your risk of severe COVID-19



Reference-www.infobae.com

Leave a Reply

Your email address will not be published. Required fields are marked *